102 research outputs found
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
No full text
Qualitatssicherung Melanom: Leitlinienbasierte Qualitatsindikatoren beim Melanom - Implementierung, Evaluation und Update-Prozess
No full textQuality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process
No full textHematological immune related adverse events after treatment with immune checkpoint inhibitors
No full textTolerability of BRAF/MEK inhibitor combinations : adverse event evaluation and management
No full text
Decision criteria and patient characteristics for patient-oriented treatment of field cancerization Standardized algorithm for personalized treatment concepts
No full textEvaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
No full text- …
